Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal

By Ed Silverman

Biotech

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

By Adam Feuerstein

Plavix
Pharmalot

Bristol-Myers and Sanofi accuse Hawaii of violating their free speech rights

By Ed Silverman

California drug prices
Pharmalot

California plans to sell its own generic drugs in hopes of lowering costs

By Ed Silverman

Pharmalot

Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval

By Ed Silverman

Celgene
Pharmalot

They did what? Celgene backs out of a $55 million deal to settle claims of thwarting generics

By Ed Silverman

Brazil generics in pharmacy
Pharmalot

Patient groups say Brazilian proposal to change patent reviews would favor pharma

By Ed Silverman

Pharmalot

Pharmalittle: Execs vow to place patients ahead of profits; conservatives like Republican drug pricing bill

By Ed Silverman

Pharmalot

Pharmalittle: The inside story of an Ebola vaccine; fewer adults received opioid prescriptions

By Ed Silverman

Pills in a box
Pharmalot

The VA approach to buying drugs means patients are less likely to skip medications due to cost

By Ed Silverman

Medication samples
Pharmalot

Florida becomes the latest state to examine Sun Pharma licenses for distributing samples

By Ed Silverman

Pharmalot

Pharmalittle: Few vets were treated with antidepressant Trump touted; Pelosi lashes out at price hikes

By Ed Silverman

California State flag
Pharmalot

Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

By Ed Silverman

Pharma

Pharmalittle: Lab urges FDA to recall all forms of Zantac; end-of-year FDA approval rush has unintended consequence

By Ed Silverman

Rising Drug Cost
Pharmalot

It’s ‘business as usual’ as many drug makers boost prices for the new year

By Ed Silverman

Pharmalot

Pharmalittle: FDA failed to police opioid prescribing program; Novo launches plan to mitigate insulin cost

By Ed Silverman

2010- 2019 Medicine
Biotech

STAT’s guide to the most important, beneficial drugs approved in the past decade

By Adam Feuerstein and Matthew Herper

Dr. Jonathan Hartwell
Matt's Take

The debate over America’s drug-pricing system is built on myths. It’s time to face reality

By Matthew Herper

FDA through the window
Pharmalot

Most Americans misunderstand approvals and FDA’s role in overseeing drug ads

By Ed Silverman

John Kapoor
Pharmalot

Prosecutors seek a 15-year jail sentence for former Insys CEO for his role in the opioid crisis

By Ed Silverman

Hires
Pharmalot

Up and Down the Ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA approves first Ebola vaccine; two big pharmacy benefit managers are joining forces

By Ed Silverman

Zolgensma
Pharmalot

As families in Europe clamor for its pricey gene therapy, Novartis creates a lottery

By Ed Silverman

Pharmalot

Pharmalittle: Novartis plans a lottery for the world’s priciest drug; Trump importation could hit Gilead

By Ed Silverman

Pharmalot

Pharmalittle: Trump proceeds with plan to allow importation; most Americans misunderstand FDA approvals

By Ed Silverman

Prescription Medication
Pharmalot

Feds says a CVS long-term-care pharmacy improperly refilled prescriptions, jeopardizing patients

By Ed Silverman

Pharmalot

Pharmalittle: Sacklers withdrew $10 billion from Purdue during opioid crisis; Purdue splits from PhRMA

By Ed Silverman

Purdue in the weeds
Business

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

By Nicholas Florko

Your daily dose of news in health and medicine

Privacy Policy